Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Clearside Biomedical, Inc.CLSD · Entity 82875 | Director | February 24, 2025 | February 24, 2025 |
| G1 Therapeutics, Inc.GTHX · Entity 87413 | 10% owner | May 30, 2018 | June 01, 2018 |
| PhaseBio Pharmaceuticals IncPHAS · Entity 113305 | Director | May 19, 2023 | May 19, 2023 |
| Vigil Neuroscience, Inc.VIGL · Entity 11675 | Director | May 16, 2022 | May 17, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Clearside Biomedical, Inc.
Report date February 24, 2025 · Filed February 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 176,141 |
Reported balance
After 2025-02-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-02-24 · Purchase · Acquired 15,000 · Balance 176,141 F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.90 to $0.9321 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: Includes an aggregate of 120,619 shares received as a pro rata distribution from Hatteras Venture Advisors III, LLC, Hatteras Venture Advisors IV SBIC, LLC, Hatteras Venture Advisors IV, LLC and Hatteras NC Fund, LP (the "Hatteras Entities"). In prior reports, the reporting person reported indirect beneficial ownership of 3,545,040 shares of the Issuer's common stock held by the Hatteras Entities. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.90 to $0.9321 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: Includes an aggregate of 120,619 shares received as a pro rata distribution from Hatteras Venture Advisors III, LLC, Hatteras Venture Advisors IV SBIC, LLC, Hatteras Venture Advisors IV, LLC and Hatteras NC Fund, LP (the "Hatteras Entities"). In prior reports, the reporting person reported indirect beneficial ownership of 3,545,040 shares of the Issuer's common stock held by the Hatteras Entities.
G1 Therapeutics, Inc.
Report date May 30, 2018 · Filed June 01, 2018
Jointly reported with Hatteras Venture Advisors IV SBIC, LLC, Hatteras Venture Partners IV SBIC, LP, INGRAM ROBERT ALEXANDER, Crumpler John, LEE KENNETH B JR, Reed Douglas MD
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 3,279,421 |
Reported balance
After 2018-05-30 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-05-30 · Sale · Disposed 758,290 · Balance 3,279,421 F1: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F2: Following the reported transaction, 3,067,962 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F3: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras NC Fund, LP ("Hatteras NC") were sold, 210,464 shares of the reportable securities are owned directly by Hatteras NC. Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 3,237,711 |
Reported balance
After 2018-05-30 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-05-30 · Sale · Disposed 41,710 · Balance 3,237,711 F1: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F4: Following the reported transaction, 168,754 shares of the reportable securities are owned directly by Hatteras NC. F5: Following the reported transaction, in which none of the reportable securities owned directly by HVP IV were sold, 3,067,962 shares of the reportable securities are owned directly by HVP IV. |
Filing footnotes · ownership attribution and instrument terms
F1: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.
F2: Following the reported transaction, 3,067,962 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
F3: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras NC Fund, LP ("Hatteras NC") were sold, 210,464 shares of the reportable securities are owned directly by Hatteras NC. Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.
F4: Following the reported transaction, 168,754 shares of the reportable securities are owned directly by Hatteras NC.
F5: Following the reported transaction, in which none of the reportable securities owned directly by HVP IV were sold, 3,067,962 shares of the reportable securities are owned directly by HVP IV.
PhaseBio Pharmaceuticals Inc
Report date May 19, 2023 · Filed May 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,693 |
Reported balance
After 2023-05-19 transaction · row 1
1 source rowRow 1 · 2023-05-19 · Exercise / conversion · Acquired 3,750 · Balance 36,693 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-05-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-05-19 · Exercise / conversion · Acquired 3,750 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F4: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,545,040 |
Reported balance
Holding disclosure · report date 2023-05-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,545,040 F2: The Reporting Person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP ("HVP IV") and Hatteras NC Fund, LP ("Hatteras NC"). HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC. F3: The Reporting Person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.
F2: The Reporting Person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP ("HVP IV") and Hatteras NC Fund, LP ("Hatteras NC"). HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.
F3: The Reporting Person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
F4: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date.
Vigil Neuroscience, Inc.
Report date May 16, 2022 · Filed May 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Hatteras Venture Partners VI, L.P. | 1,556,030 |
Last balance in matching sequence
After 2022-05-17 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-05-16 · Purchase · Acquired 21,802 · Balance 1,541,137 F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.50 to $2.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. F2: These shares are held directly by Hatteras Venture Partners VI, L.P. ("Hatteras VI"). Hatteras Venture Advisors VI, LLC ("HVA VI") is the general partner of Hatteras VI. The Reporting Person is a managing member of HVA VI and disclaims beneficial ownership of the shares held by Hatteras VI except to the extent of his pecuniary interest therein, if any. Row 2 · 2022-05-17 · Purchase · Acquired 14,893 · Balance 1,556,030 F3: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.76 to $3.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. F2: These shares are held directly by Hatteras Venture Partners VI, L.P. ("Hatteras VI"). Hatteras Venture Advisors VI, LLC ("HVA VI") is the general partner of Hatteras VI. The Reporting Person is a managing member of HVA VI and disclaims beneficial ownership of the shares held by Hatteras VI except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | Direct | 3,000 |
Reported balance
Holding disclosure · report date 2022-05-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.50 to $2.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected.
F2: These shares are held directly by Hatteras Venture Partners VI, L.P. ("Hatteras VI"). Hatteras Venture Advisors VI, LLC ("HVA VI") is the general partner of Hatteras VI. The Reporting Person is a managing member of HVA VI and disclaims beneficial ownership of the shares held by Hatteras VI except to the extent of his pecuniary interest therein, if any.
F3: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.76 to $3.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries C-1 Preferred Stock · Derivative | 149,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 33 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 0 Underlying: Common Stock · 149,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries B Preferred Stock · Derivative | 94,874 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 32 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 0 Underlying: Common Stock · 94,874 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries B Preferred Stock · Derivative | 1,044,764 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 31 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 0 Underlying: Common Stock · 1,044,764 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries AA Preferred Stock · Derivative | 13,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 30 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 0 Underlying: Common Stock · 13,609 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries AA Preferred Stock · Derivative | 174,699 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 29 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 0 Underlying: Common Stock · 174,699 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries 1 Preferred Stock · Derivative | 4,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 28 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Catalysta Ventures, LLC Disclosed balance after: 0 Underlying: Common Stock · 4,846 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Catalysta Ventures, LLC ("Catalysta") is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta. The reporting person is a manager of Catalysta and may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The reporting person disclaims beneficial ownership of the securities held by Catalysta and HVP I except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries 1 Preferred Stock · Derivative | 3,862 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 27 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 0 Underlying: Common Stock · 3,862 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries 1 Preferred Stock · Derivative | 42,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 26 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 0 Underlying: Common Stock · 42,530 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries 1 Preferred Stock · Derivative | 52,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 25 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners I, LP Disclosed balance after: 0 Underlying: Common Stock · 52,690 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Catalysta Ventures, LLC ("Catalysta") is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta. The reporting person is a manager of Catalysta and may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The reporting person disclaims beneficial ownership of the securities held by Catalysta and HVP I except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | SaleSeries C-1 Preferred Stock · Derivative | 994 | $5.00 | $4,970.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 24 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Venture Capital Multiplier Fund Disclosed balance after: 40,420 Underlying: Common Stock · 994 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionSeries C-1 Preferred Stock · Derivative | 41,414 | $0.12 | $4,969.68 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 23 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Venture Capital Multiplier Fund Disclosed balance after: 41,414 Underlying: Common Stock · 41,414 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionWarrants to Purchase Series C-1 Preferred Stock · Derivative | 41,414 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 22 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Venture Capital Multiplier Fund Disclosed balance after: 0 Underlying: Series C-1 Preferred Stock · 41,414 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F1 · derivative.underlying: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | SaleSeries C-1 Preferred Stock · Derivative | 104 | $5.00 | $520.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 21 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 13,558 Underlying: Common Stock · 104 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionSeries C-1 Preferred Stock · Derivative | 4,309 | $0.12 | $517.08 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 20 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 13,662 Underlying: Common Stock · 4,309 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionWarrants to Purchase Series C-1 Preferred Stock · Derivative | 4,309 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 19 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 0 Underlying: Series C-1 Preferred Stock · 4,309 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F1 · derivative.underlying: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | SaleSeries C-1 Preferred Stock · Derivative | 1,139 | $5.00 | $5,695.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 18 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 149,320 Underlying: Common Stock · 1,139 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionSeries C-1 Preferred Stock · Derivative | 47,458 | $0.12 | $5,694.96 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 17 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 150,459 Underlying: Common Stock · 47,458 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionWarrants to Purchase Series C-1 Preferred Stock · Derivative | 47,458 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 16 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 0 Underlying: Series C-1 Preferred Stock · 47,458 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F1 · derivative.underlying: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | SaleSeries B Preferred Stock · Derivative | 42 | $5.00 | $210.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 15 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 94,874 Underlying: Common Stock · 42 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionSeries B Preferred Stock · Derivative | 1,731 | $0.12 | $207.72 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 14 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 94,916 Underlying: Common Stock · 1,731 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionWarrants to Purchase Series B Preferred Stock · Derivative | 1,731 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 13 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 0 Underlying: Series B Preferred Stock · 1,731 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F1 · derivative.underlying: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | SaleSeries B Preferred Stock · Derivative | 458 | $5.00 | $2,290.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 12 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 1,044,764 Underlying: Common Stock · 458 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionSeries B Preferred Stock · Derivative | 19,061 | $0.12 | $2,287.32 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 11 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 1,045,222 Underlying: Common Stock · 19,061 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionWarrants to Purchase Series B Preferred Stock · Derivative | 19,061 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 10 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 0 Underlying: Series B Preferred Stock · 19,061 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F1 · derivative.underlying: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | PurchaseCommon Stock | 150,000 | $5.00 | $750,000.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · nonDerivative · entry 9 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Venture Capital Multiplier Fund Disclosed balance after: 416,481 F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionCommon Stock | 266,481 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · nonDerivative · entry 8 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Venture Capital Multiplier Fund Disclosed balance after: 266,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionCommon Stock | 4,846 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · nonDerivative · entry 7 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Catalysta Ventures, LLC Disclosed balance after: 4,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Catalysta Ventures, LLC ("Catalysta") is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta. The reporting person is a manager of Catalysta and may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The reporting person disclaims beneficial ownership of the securities held by Catalysta and HVP I except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | PurchaseCommon Stock | 12,487 | $5.00 | $62,435.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · nonDerivative · entry 6 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 163,099 F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionCommon Stock | 150,612 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · nonDerivative · entry 5 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 150,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | PurchaseCommon Stock | 137,513 | $5.00 | $687,565.00 |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · nonDerivative · entry 4 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 1,820,933 F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionCommon Stock | 1,683,420 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · nonDerivative · entry 3 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 1,683,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionCommon Stock | 52,690 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-056051 · doc4.xml · nonDerivative · entry 2 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners I, LP Disclosed balance after: 52,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Catalysta Ventures, LLC ("Catalysta") is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta. The reporting person is a manager of Catalysta and may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The reporting person disclaims beneficial ownership of the securities held by Catalysta and HVP I except to the extent of his pecuniary interest therein. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 21:23 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 11,250 | $0.00 Strike: $10.74 | $0.00 |
DisclosureSEC source: 0001209191-18-038988 · doc4.xml · derivative · entry 1 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires 2028-06-19 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2019. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 18:22 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 41,710 | $48.00 | $2,002,080.00 |
DisclosureSEC source: 0001209191-18-034839 · doc4.xml · nonDerivative · entry 2 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,237,711 F1 · ownership.nature: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F4 · ownership.nature: Following the reported transaction, 168,754 shares of the reportable securities are owned directly by Hatteras NC. F5 · ownership.nature: Following the reported transaction, in which none of the reportable securities owned directly by HVP IV were sold, 3,067,962 shares of the reportable securities are owned directly by HVP IV. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 18:22 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 758,290 | $48.00 | $36,397,920.00 |
DisclosureSEC source: 0001209191-18-034839 · doc4.xml · nonDerivative · entry 1 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,279,421 F1 · ownership.nature: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F2 · ownership.nature: Following the reported transaction, 3,067,962 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F3 · ownership.nature: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras NC Fund, LP ("Hatteras NC") were sold, 210,464 shares of the reportable securities are owned directly by Hatteras NC. Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. Read SEC document |
| May 23, 2018 Filed May 23, 2018 20:46 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 26 | $50.50 | $1,313.00 |
DisclosureSEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 8 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,037,711 F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F12 · ownership.nature: Following the reported transaction, 3,826,252 shares of the reportable securities are owned directly by HVP IV. F13 · ownership.nature: Following the reported transaction, 210,464 shares of the reportable securities are owned directly by Hatteras NC. Read SEC document |
| May 23, 2018 Filed May 23, 2018 20:46 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 474 | $50.50 | $23,937.00 |
DisclosureSEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 7 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,037,737 F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F11 · ownership.nature: Following the reported transaction, 210,490 shares of the reportable securities are owned directly by Hatteras NC. F12 · ownership.nature: Following the reported transaction, 3,826,252 shares of the reportable securities are owned directly by HVP IV. Read SEC document |
| May 22, 2018 Filed May 23, 2018 20:46 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 308 | $50.69 | $15,611.01 |
DisclosureSEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 6 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,038,211 F9 · price: The price represents the weighted average price with a low of $50.50 and a high of $51.25. F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F10 · ownership.nature: Following the reported transaction, 3,826,726 shares of the reportable securities are owned directly by HVP IV. F11 · ownership.nature: Following the reported transaction, 210,490 shares of the reportable securities are owned directly by Hatteras NC. Read SEC document |
| May 22, 2018 Filed May 23, 2018 20:46 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 5,592 | $50.86 | $284,405.21 |
DisclosureSEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 5 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,038,519 F9 · price: The price represents the weighted average price with a low of $50.50 and a high of $51.25. F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F8 · ownership.nature: Following the reported transaction, 210,798 shares of the reportable securities are owned directly by Hatteras NC. F10 · ownership.nature: Following the reported transaction, 3,826,726 shares of the reportable securities are owned directly by HVP IV. Read SEC document |
| May 21, 2018 Filed May 23, 2018 20:46 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 26 | $52.13 | $1,355.38 |
DisclosureSEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 4 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,044,111 F6 · price: The price represents the weighted average price with a low of $52.12 and a high of $52.14. F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F7 · ownership.nature: Following the reported transaction, 3,832,318 shares of the reportable securities are owned directly by HVP IV. F8 · ownership.nature: Following the reported transaction, 210,798 shares of the reportable securities are owned directly by Hatteras NC. Read SEC document |
| May 21, 2018 Filed May 23, 2018 20:46 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 474 | $52.13 | $24,709.62 |
DisclosureSEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 3 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,044,137 F6 · price: The price represents the weighted average price with a low of $52.12 and a high of $52.14. F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F5 · ownership.nature: Following the reported transaction, 210,824 shares of the reportable securities are owned directly by Hatteras NC. F7 · ownership.nature: Following the reported transaction, 3,832,318 shares of the reportable securities are owned directly by HVP IV. Read SEC document |
| May 21, 2018 Filed May 23, 2018 20:46 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 1,595 | $51.06 | $81,438.95 |
DisclosureSEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 2 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,044,611 F1 · price: The price represents the weighted average price with a low of $51.00 and a high of $51.755. The Reporting Persons undertake to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4. F2 · ownership.nature: Following the reported transaction, 3,832,792 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F5 · ownership.nature: Following the reported transaction, 210,824 shares of the reportable securities are owned directly by Hatteras NC. Read SEC document |
| May 21, 2018 Filed May 23, 2018 20:46 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 29,005 | $51.16 | $1,483,907.40 |
DisclosureSEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 1 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,046,206 F1 · price: The price represents the weighted average price with a low of $51.00 and a high of $51.755. The Reporting Persons undertake to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4. F2 · ownership.nature: Following the reported transaction, 3,832,792 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F3 · ownership.nature: Following the reported transaction, 212,419 shares of the reportable securities are owned directly by Hatteras NC Fund, LP ("Hatteras NC"). Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC Fund, LP. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member" and collectively, the "HVA IV Managing Members"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. Read SEC document |
| May 18, 2018 Filed May 21, 2018 20:05 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | SaleCommon Stock | 61,139 | $13.16 | $804,589.24 |
DisclosureSEC source: 0001209191-18-031802 · doc4.xml · nonDerivative · entry 2 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,466,394 F5 · shares: Consists of (i) 1,737 shares sold by Hatteras NC, (ii) 23,497 shares sold by HVP III, (iii) 2,108 shares sold by HVA III, (iv) 3,791 shares sold by HVP IV and (v) 30,006 shares sold by HVP IV SBIC. F6 · price: This transaction was executed in multiple trades at prices ranging from $12.97 to $13.41, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC. F4 · ownership.nature: The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:05 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | SaleCommon Stock | 100,000 | $13.03 | $1,303,000.00 |
DisclosureSEC source: 0001209191-18-031802 · doc4.xml · nonDerivative · entry 1 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,527,533 F1 · shares: Consists of (i) 3,000 shares sold by Hatteras NC Fund, LP ("Hatteras NC"), (ii) 38,300 shares sold by Hatteras Venture Partners III, LP ("HVP III"), (iii) 3,500 shares sold by Hatteras Venture Affiliates III, LP ("HVA III"), (iv) 6,200 shares sold by Hatteras Venture Partners IV, LP ("HVP IV") and (v) 49,000 shares sold by Hatteras Venture Partners IV SBIC, LP ("HVP IV SBIC"). F2 · price: This transaction was executed in multiple trades at prices ranging from $12.23 to $13.37, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC. F4 · ownership.nature: The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| March 23, 2018 Filed Mar 23, 2018 21:51 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | SaleCommon Stock | 5,231 | $12.02 | $62,876.62 |
DisclosureSEC source: 0001209191-18-021497 · doc4.xml · nonDerivative · entry 3 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,627,533 F7 · shares: Consists of (i) 154 shares sold by Hatteras NC, (ii) 2,006 shares sold by HVP III, (iii) 182 shares sold by HVA III, (iv) 324 shares sold by HVP IV and (v) 2,565 shares sold by HVP IV SBIC. F8 · price: This transaction was executed in multiple trades at prices ranging from $12.00 to $12.10, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC. F4 · ownership.nature: The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| March 22, 2018 Filed Mar 23, 2018 21:51 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | SaleCommon Stock | 33,630 | $12.07 | $405,914.10 |
DisclosureSEC source: 0001209191-18-021497 · doc4.xml · nonDerivative · entry 2 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,632,764 F5 · shares: Consists of (i) 989 shares sold by Hatteras NC, (ii) 12,897 shares sold by HVP III, (iii) 1,170 shares sold by HVA III, (iv) 2,085 shares sold by HVP IV and (v) 16,489 shares sold by HVP IV SBIC. F6 · price: This transaction was executed in multiple trades at prices ranging from $12.00 to $12.21, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC. F4 · ownership.nature: The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| March 21, 2018 Filed Mar 23, 2018 21:51 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | SaleCommon Stock | 100,000 | $12.27 | $1,227,000.00 |
DisclosureSEC source: 0001209191-18-021497 · doc4.xml · nonDerivative · entry 1 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,666,394 F1 · shares: Consists of (i) 2,940 shares sold by Hatteras NC Fund, LP ("Hatteras NC"), (ii) 38,350 shares sold by Hatteras Venture Partners III, LP ("HVP III"), (iii) 3,480 shares sold by Hatteras Venture Affiliates III, LP ("HVA III"), (iv) 6,200 shares sold by Hatteras Venture Partners IV, LP ("HVP IV") and (v) 49,030 shares sold by Hatteras Venture Partners IV SBIC, LP ("HVP IV SBIC"). F2 · price: This transaction was executed in multiple trades at prices ranging from $12.00 to $12.49, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC. F4 · ownership.nature: The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| December 07, 2017 Filed Dec 7, 2017 22:10 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | SaleCommon Stock | 5,000 | $6.13 | $30,650.00 |
DisclosureSEC source: 0001209191-17-064491 · doc4.xml · nonDerivative · entry 3 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,766,394 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on June 12, 2017. F8 · shares: Consists of (i) 4,584 shares sold by HVP III and (ii) 416 shares sold by HVA III. F9 · price: This transaction was executed in multiple trades at prices ranging from $5.85 to $6.35, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F4 · ownership.nature: The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of Hatteras Venture Partners IV SBIC, LP; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP. HVP III, HVA III, Hatteras Venture Partners IV SBIC, LP, Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, Hatteras Venture Partners IV SBIC, LP, Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP. F5 · ownership.nature: The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| December 06, 2017 Filed Dec 7, 2017 22:10 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | SaleCommon Stock | 15,000 | $6.09 | $91,350.00 |
DisclosureSEC source: 0001209191-17-064491 · doc4.xml · nonDerivative · entry 2 Thorp Clay · CIK 0001592380 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,771,394 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on June 12, 2017. F6 · shares: Consists of (i) 13,751 shares sold by HVP III and (ii) 1,249 shares sold by HVA III. F7 · price: This transaction was executed in multiple trades at prices ranging from $5.93 to $6.26, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F4 · ownership.nature: The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of Hatteras Venture Partners IV SBIC, LP; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP. HVP III, HVA III, Hatteras Venture Partners IV SBIC, LP, Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, Hatteras Venture Partners IV SBIC, LP, Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP. F5 · ownership.nature: The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.